A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2016
At a glance
- Drugs GKT 831 (Primary)
- Indications Diabetic nephropathies
- Focus Proof of concept; Therapeutic Use
- Sponsors GenKyoTex
- 31 Aug 2018 Biomarkers information updated
- 09 Sep 2015 Primary endpoint (Albuminuria) has not been met, according to a Genkyotex media release.
- 09 Sep 2015 Results published in a Genkyotex media release.